

Supporting Information

Poly-Electrophilic Sesquiterpene Lactones from *Vernonia amygdalina*: New Members and Differences in their Mechanism of Thiol-Trapping and in Bioactivity

Annamaria Sinisi,[†] Estrella Millán,[‡] Solomon M. Abay,^{§,⊥} Annette Habluetzel,[§]
Giovanni Appendino,[Ⓛ] Eduardo Muñoz,[‡] and Orazio Taglialatela-Scafati^{†,*}

[†] *Dipartimento di Farmacia, Università di Napoli Federico II, Via Montesano 49, 80131 Napoli, Italy*

[‡] *Maimónides Institute for Research in Biomedicine of Córdoba, Reina Sofía University Hospital, University of Córdoba, Avda Menéndez Pidal s/n. 14004. Córdoba, Spain.*

[§] *School of Pharmacy, University of Camerino, Piazza dei Costanti, 62032 Camerino, (MC) Italy*

[⊥] *School of Medicine, College of Health Sciences, Addis Ababa University, 62212 Addis Ababa, Ethiopia*

[Ⓛ] *Dipartimento di Scienze Chimiche, Alimentari, Farmaceutiche e Farmacologiche, Via Bovio 6, 28100, Novara, Italy*

Table of Contents

Figure S1. ^1H NMR spectrum (700 MHz) of vernomygdalin (**8**) in CDCl_3 .

Figure S2. 2D COSY NMR spectrum (500 MHz) of vernomygdalin (**8**) in CDCl_3 .

Figure S3. 2D HMBC NMR spectrum (500 MHz) of vernomygdalin (**8**) in CDCl_3 .

Figure S4. ^1H NMR spectrum (700 MHz) of methylvernolide (**2**) in CDCl_3 .

Figure S5. 2D COSY NMR spectrum (500 MHz) of methylvernolide (**2**) in CDCl_3 .

Figure S6. ^1H NMR spectrum (500 MHz) of deoxyvernodalol (**6**) in CDCl_3 .

Figure S7. ^1H NMR spectrum (500 MHz) of vernolide (**1**) in CDCl_3 .

Figure S8. ^1H NMR spectrum (500 MHz) of vernodalol (**5**) in CDCl_3 .

Figure S9. Low-field region of the ^1H NMR spectrum (500 MHz) of a 1:1 mixture of vernolide (**1**) and vernodalol (**5**) in $\text{DMSO}-d_6$.

Figure S10. Low-field region of the ^1H NMR spectrum (500 MHz) of a 1:1 mixture of vernolide (**1**) and vernodalol (**5**) in $\text{DMSO}-d_6$ 15 min. after addition of 1 equiv. of cysteamine.

Figure S1. ^1H NMR spectrum (700 MHz) of venomygdalin (**8**) in CDCl_3




Figure S2. 2D COSY NMR spectrum (500 MHz) of vernomygdalin (**8**) in CDCl_3 .




Figure S3. 2D HMBC NMR spectrum (500 MHz) of vernomygdalin (**8**) in CDCl₃.




Figure S4. ¹H NMR spectrum (700 MHz) of methylvernolide (**2**) in CDCl₃




Figure S5. 2D COSY NMR spectrum (500 MHz) of methylvernolide (**2**) in CDCl₃.




Figure S6. ¹H NMR spectrum (500 MHz) of deoxyvernodalol (**6**) in CDCl₃.




Figure S7. ^1H NMR spectrum (500 MHz) of vernolide (**1**) in CDCl_3




Figure S8. ^1H NMR spectrum (500 MHz) of vernodalol (**5**) in CDCl_3




Figure S9. Low-field region of the ^1H NMR spectrum (500 MHz) of a 1:1 mixture of vernolide (**1**) and vernodalol (**5**) in DMSO-d_6 .




Figure S10. Low-field region of the ^1H NMR spectrum (500 MHz) of a 1:1 mixture of vernolide (**1**) and vernodalol (**5**) in DMSO-d_6 15 min. after addition of 1 equiv. of cysteamine

